Search

The article offers the author's insights on the importance of the electronic informed consent, which is a key to support patient-centric mantra in clinical trials. Topics discussed include the guidance on informed consent published by the U.S. Food and Drug Administration (FDA), various recommendations to obtain patient agreement which include clinical trials description, treatment benefits, and confidentiality, and the significance of language on patient's understanding on informed consent.

The article discusses the importance of electrocardiogram (ECG) reading on clinical research and practice. It stresses that it is critical in data collection during clinical research with the investigational drug's cardiac safety profile, especially the interval duration measurements of heart activity, emphasizing ECG centralization. It suggests that relevance of the findings should also be associated with one's prior history and current health status.

The article discusses the scientific approach in the centralization of electrocardiogram (ECG) Phase III on cardiac safety risk assessment. It emphasizes the QT wave interval prolongation, or the contraction and repolarization of cardiac muscles, on polymorphic ventricular tachycardia or torsades de pointes during drug interaction. The clinical trial "Thorough QT/QTc (TQT) Study" promotes cardiac safety data collection associated with market drugs and further enhances assessment.

The article discusses the implication of electrocardiography (ECG) in the development of drugs as well as the use of laboratories. According to the article, ECGs are used to gather information as well as assess the effect of investigational drugs on the electrical functions of the heart. In addition, it states that sponsors should consider several factors such as reducing the price they pay for research since it does not give them the assurance that all the results are correct. INSET: Homework for Sponsors.